readthroughSign in
CompanyOTLKNasdaqIselin, NJ

Outlook Therapeutics, Inc.

Outlook Therapeutics develops LYTENAVA, an ophthalmic formulation of bevacizumab for wet age-related macular degeneration.

SCHEDULE 13G/ANov 16Latest SEC filing
Aug 27Latest story